Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Four leading experts in respiratory allergy spotlight the impact of respiratory allergy in children, in an ALK-sponsored symposium at the EAACI CongressThe growing availability of evidence-based...
-
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): ALK igangsætter et klinisk fase I-studie med sin nye, sublinguale tabletvaccine (SLIT-tablet) til behandling af peanutallergi. Studiet markerer den...
-
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): ALK initiates a Phase I clinical trial of its novel investigational sublingual allergy immunotherapy (SLIT) tablet for the treatment of peanut allergy. The...
-
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af...
-
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the...
-
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af...
-
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the...
-
Bemærk venligst, at rapporten udelukkende findes på engelsk ALK reports Q1 revenue growth of 11% with tablet sales up 24% and earnings up 20% (unaudited) ALK delivered strong financial performance...
-
ALK reports Q1 revenue growth of 11% with tablet sales up 24% and earnings up 20% (unaudited) ALK delivered strong financial performance in Q1, with revenue up 11% and tablets as the primary driver...
-
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) offentliggør delårsrapport for første kvartal 2022 torsdag den 12. maj 2022. ALK afholder samme dag kl. 13.30 (CEST) en telefonkonference for investorer...